MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors

Table 1

MET expression in primary and metastatic renal cell carcinoma (RCC).

	Primary RCC
	High MET # (%)	Low MET # (%)	Total cases
Metastatic RCC
High MET # (%)	10 (58.8%)	6 (42.9%)	16
Low MET # (%)	7 (41.2%)	8 (57.1%)	15
Total cases	17	14	31